英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

mongrel    
n. 杂种,杂种狗,混血儿
a. 杂种的,混血儿的

杂种,杂种狗,混血儿杂种的,混血儿的

mongrel
n 1: derogatory term for a variation that is not genuine;
something irregular or inferior or of dubious origin; "the
architecture was a kind of bastard suggesting Gothic but
not true Gothic" [synonym: {bastard}, {mongrel}]
2: an inferior dog or one of mixed breed [synonym: {cur}, {mongrel},
{mutt}]

Mongrel \Mon"grel\, n. [Prob. shortened fr. mongrel, and akin to
AS. mengan to mix, and E. mingle. See {Mingle}.]
The progeny resulting from a cross between two breeds, as of
domestic animals; anything of mixed breed. --Drayton.
[1913 Webster]


Mongrel \Mon"grel\, a.
1. (Zool.) Not of a pure breed.
[1913 Webster]

2. Of mixed kinds; as, mongrel language.
[1913 Webster]

61 Moby Thesaurus words for "mongrel":
Cape Colored, Eurasian, animal, bastard, beast, cattalo, citrange,
cross, crossbred, crossbreed, crossed, cur, dog, griffe,
half blood, half-bred, half-breed, half-caste, high yellow, hinny,
hound, hybrid, hyena, insect, interbred, ladino, liger, lurcher,
mestee, mestiza, mestizo, metis, metisse, mixblood, mixed-blood,
mulatto, mule, mustee, mutt, octoroon, pariah dog, pig, plumcot,
polecat, quadroon, quintroon, reptile, sambo, serpent, skunk,
snake, swine, tangelo, tigon, varmint, vermin, viper, whelp, worm,
zebrass, zebrule


请选择你想看的字典辞典：
单词字典翻译
Mongrel查看　Mongrel　在百度字典中的解释百度英翻中〔查看〕
Mongrel查看　Mongrel　在Google字典中的解释Google英翻中〔查看〕
Mongrel查看　Mongrel　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment . . .
    FDA approved of Regeneron Pharmaceutical’s Libtayo (cemiplimab-rwlc)as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) who are at an increased risk of recurrence following surgery and radiation 1 Libtayo was reviewed by FDA under Priority Review, a method reserved for medicines representing a potential improvement in efficacy or safety in treatments of
  • label - accessdata. fda. gov
    LIBTAYO (cemiplimab-rwlc) injection for intravenous use is a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution with a pH of 6
  • Libtayo (cemiplimab-rwlc) FDA Approval History - Drugs. com
    Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC)
  • Behind the FDA Approval: Adjuvant Cemiplimab Shifts Treatment . . .
    Vishal A Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma On October 8, 2025, the US FDA approved the immunotherapy cemiplimab-rwlc (Libtayo) for adjuvant treatment of adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
    The FDA evaluated Libtayo under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions An additional regulatory application is also under review in the European Union, with a decision expected by the first half of 2026
  • FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCC
    Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo The Food and Drug Administration (FDA) has approved Libtayo ® (cemiplimab-rwlc) for the adjuvant treatment of adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation
  • FDA Approves Cemiplimab for Adjuvant Cutaneous Squamous Cell . . .
    The US FDA has approved the supplemental biologics license application (sBLA) for cemiplimab-rwlc (Libtayo) as adjuvant treatment in adults with high-risk cutaneous squamous cell carcinoma (CSCC) 1 The sBLA approval was based on an extensive review of data from the pivotal phase 3 C-POST study (NCT03969004) which demonstrated a statistically significant and clinically meaningful improvement
  • FDA Approves Cemiplimab (Libtayo) for Cutaneous Squamous Cell . . .
    The U S Food and Drug Administration approved adjuvant cemiplimab (Libtayo) for adults with cutaneous squamous cell carcinoma who are at a high risk for recurrence after surgery and radiation





中文字典-英文字典  2005-2009